Immunogenicity of the Brazilian hepatitis B vaccine in adults;Imunogenicidade da vacina brasileira contra hepatite B em adultos

Revista de Saude Publica

Volumn 44, Issue 2, 2010, Pages 353-359

  de Moraes, José Cássio ^a   de Albuquerque Luna, Expedito José ^b   Grimaldi, Rosária Amélia ^c  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Grupo de Estudo em Leishmaniose   (Brazil)

Author keywords

Controlled clinical trial; Efficacy; Hepatitis B; Hepatitis B vaccines; Prevention control

Indexed keywords

EID: 77953940713     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-89102010000200017     Document Type: Article

References (17)

1. Braga WSM, Brasil LM, Souza RAB, Castilho MC, Fonseca JC. Ocorrência da infecção pelo vírus da hepatite B (VHB) e delta (VHD) em sete grupos indígenas do estado do Amazonas. Rev Soc Bras Med Trop. 2001;34(4):349-55. DOI:10.1590/S0037- 86822001000400007
2. Costa AA, Inenami M, Juarez E, Llacen PD, Raw I. Preliminary Report of the Use of a Recombinant Yeast- derived Hepatitis B Vaccine Manufactured by Instituto Butantan. Rev Inst Med Trop Sao Paulo. 1997;39(1):39- 42. DOI:10.1590/S0036-46651997000100008
3. Desombere I, Hanser P, Rossau R, Paradijs J, Leroux- Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol. 1995;154:520-9.
4. El-Khouri M, Duarte LS, Ribeiro RB, Silva LFF, Camargo LMA, Santos VA, et al. Seroprevalence of hepatitis B vírus and hepatitis C vírus in Monte Negro in the Brazilian Western Amazon. Clinics (Sao Paulo). 2005;60(1):29-36. DOI:10.1590/S1807- 59322005000100007
5. Figueiredo GM, Breve histórico da emergência da hepatite B como problema de saúde pública. J Bras AIDS. 2006;8(1):8-13.
6. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy and indications for immunization. Curr Clin Top Infect Dis. 1982;12:282- 308.
7. Ioshimoto LM, Rissato ML, Bonilha VSJ, Miyaki C, Raw I, Granovski N. Safety and immuunogenicity of hepatitis B vaccine Butang in adults. Rev Inst Med Trop Sao Paulo. 1999;41(3):191-3. DOI:10.1590/S0036- 46651999000300011
8. Leroux-Roels G, Desombere I, Cobbaut L, Petit MA, Desmons P, Hauser P, et al. Hepatitis B vaccine containing surface antingen and selected preS1 and preS2 sequences - Immunogenicity in poor responders to hepatitis B vaccines. Vaccine. 1997;15(16):1732-6. DOI:10.1016/S0264-410X(97)00118-7
9. Martins RM, Bensabath, Arraes LC, Oliveira ML, Miguel JC, Barbosa GG, et al. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz. 2004;99(8):865-71. DOI:10.1590/S0074- 02762004000800014
10. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-31.
11. Pillot J, Poynard T, Elias A, Maillard J, Lazizi Y, Brancer M, et al. Weak immunogenicity of the Pre-S2 sequence and lack of circumventing effect on the unresponsiveness to the Hepatitis B virus vaccine. Vaccine. 1995;13(3):289-94. DOI:10.1016/0264- 410X(95)93316-2
12. Resti M, Azzari C, Mannelli F, Rossi ME, Lionetti P, Vierucci A. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine. 1997;15(12-13):1338-40. DOI:10.1016/S0264-410X(97)00028-5
13. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity- 'vaccinosis': a dangerous liaison? Autoimmun. 2000;14(1):1-10. DOI:10.1006/ jaut.1999.0346
14. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controller clinical trial in a high risk population in the United States. N Engl J Med. 1980;303(15):833-41.
15. Trivello R, Chiaramonte M, Ngatchu T, Baldo V, Majori S, Moschen ME, et al. Persistence of anti-AgHBs antibodies in health care personnel to recombinant DNA HB booster vaccine. Vaccine. 1995;13(2):139- 41. DOI:10.1016/0264-410X(95)93126-T
16. Viana S, Paraná R, Moreira RC, Compri AD, Macedo V, High prevalence of hepatitis B vírus and hepatitis D virus in the Brazilian Western Amazon. Am J Trop Med Hyg. 2005;73(4):808-14.
17. World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. Geneva; 2004. (WHO Technical Report series, 924)